Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P42574 (
caspase-3
)
45,978
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Background:
Renal cell carcinoma (RCC) is one of the most common and malignant tumors in the urinary system. This article set out with the aim of investigating the mechanism and clinical significance of
miR-4461
in the RCC progression.
Materials and Methods:
Twenty-eight (28) paired RCC tissue samples and adjacent nontumor tissue samples, as well as RCC cell lines were used to measure the expression of
miR-4461
and protein phosphatase 1 regulatory subunit 3C (
PPP1R3C
) transcript by real-time quantitative PCR. The target relationship between
miR-4461
and
PPP1R3C
was predicted by TargetScan and further verified by dual-luciferase reporter gene assay and RNA pull-down assay. Cell Counting Kit-8 (CCK-8) assay and BrdU ELISA assay were implemented to measure RCC cell viability and proliferation. In addition,
caspase-3
activity assay and cell adhesion assay were implemented to measure RCC cell apoptosis and adhesion.
Results:
MiR-4461
was lowly expressed both in RCC tissues and cells, while upregulated
PPP1R3C
was tested in RCC tissues and cells. In addition,
miR-4461
was validated to directly target
PPP1R3C
, thereby negatively regulating
PPP1R3C
. Particularly,
miR-4461
exerted a clear inhibitory effect on the malignant phenotypes of RCC cells by binding and inhibiting
PPP1R3C
.
Conclusion:
MiR-4461
, which served as a tumor suppressor, inhibited RCC progression by targeting and downregulating
PPP1R3C
.
...
PMID:
MiR-4461
Inhibits Tumorigenesis of Renal Cell Carcinoma by Targeting
PPP1R3C
. 3291 48